LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Biomanufacturing Policy Summit Report 2024: Policy pathways for biomanufacturing in Europe

    14/05/2024

    REPORT

    Brussels, 14 May 2024 - The Biomanufacturing Policy Summit is an annual meeting organised by EuropaBio that brings together biotech industry representatives and policymakers to discuss the most timely and relevant topics for biomanufacturing across sectors. The 2024 edition occurred in Brussels on 13th March and gathered 73 participants, including participants from the European Commission and the European Parliament.

    “Policy pathways for biomanufacturing in Europe” was the Summit theme and the umbrella topic for discussions on the best ways to defragment and accelerate biomanufacturing in the EU, plus biomanufacturing policies from other global regions. It is a critical timing for biomanufacturing, as different policy files are underway at EU level, with an impact on relevant products or processes including biopharmaceuticals, new genomic techniques, detergents, alternative proteins and cell-cultivation .

    This report summarizes the Summit’s main discussion points and takeaways and uses them as a foundation to build a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis for biomanufacturing in Europe. The analysis is further refined with data from recent reports and examples provided by EuropaBio's members, in order to add evidence and practical examples to support the arguments. Following the 2023 report which presented 10 recommendations for biomanufacturing, the 2024 SWOT analysis aims to act as an open conclusion from the Summit, adding substance to the ongoing debate around biomanufacturing in Europe.

    The report stresses the urgent need to address the question “What does the EU want to be?” and build an answer with pillars in innovation, skills, smart and agile legislation and financial instruments, and the Single Market. The EU needs a smart industrial policy for biotech and biomanufacturing rooted in science-based policymaking, which promotes and incentivises the scale-up of infrastructures and sustainable solutions and creates innovative and resilient supply-chains, whilst answering the EU’s long-term ambitions.

    Biomanufacturing Policy Summit Report 2024: Policy pathways for biomanufacturing in Europe


    Download
    Share
    Communications Team
    Communications Team

    Related posts

    23/04/2026

    ITRE’s recognition of the importance of biomanufacturing and of biotechnology as a horizontal enabling technology for Europe’s future in the European Competitiveness Fund


    Read more
    06/02/2026

    OECD: A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States


    Read more
    13/01/2026

    Response to the EC Call for Evidence on the Advanced Materials Act


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.